Recent Insights in Dermatology: A Review of 2024(January to June) Highlights


JAMA Dermatology Highlights

May 2024 Issue:

1. Barriers and Facilitators to Long-term Antibiotic Prescriptions for Acne Treatment: This study explores the challenges and enabling factors in prescribing long-term antibiotics for acne, providing valuable insights for dermatologists.

2. Onset of Interstitial Lung Disease in MDA5-Positive Dermatomyositis: An assessment of the timing of interstitial lung disease in patients with MDA5 antibody-positive dermatomyositis.

3. Tofacitinib for Pretibial Myxedema: Evaluation of the effectiveness of Tofacitinib in treating pretibial myxedema.

4. Keratoacanthomas and Cutaneous Squamous Cell Carcinomas with PD-1 and PD-L1 Inhibitors: Analysis of the use of PD-1 and PD-L1 inhibitors in treating these skin cancers.

5. Health-Related Quality of Life in Psoriasis Patients: A systematic review of patient-reported outcomes measuring the quality of life in individuals with psoriasis.

6. Emergency Contraception for Patients on Isotretinoin: Discussion on the use of emergency contraception in patients taking isotretinoin.

vitiligo treatment

April 2024 Issue:

1. Expert Recommendations on Topical Vitiligo Treatments for Children and Adolescents: Guidelines for the topical treatment of vitiligo in young patients.

2. Cognitive Impairment Symptoms in Children with Atopic Dermatitis: Investigating the symptoms of cognitive impairment in children suffering from atopic dermatitis.

3. Spesolimab Monoclonal Antibody (IL36R) for Pustulosis: Treatment case study of a girl with continuous acrodermatitis using Spesolimab monoclonal antibody.

March 2024 Issue:

1. Papular Mucinosis: In-depth exploration of this skin condition.

2. Short-term Cardiovascular Complications in Dermatology Patients Using JAK-STAT Inhibitors: A meta-analysis of randomized clinical trials.

February 2024 Issue:

1. Etiology and Clinical Manifestations of Drug-Induced Dermatomyositis: Examination of the causes and symptoms of drug-induced dermatomyositis.

2. Anifrolumab for Refractory Juvenile Dermatomyositis: Study on the rapid relief provided by Anifrolumab in treating severe juvenile dermatomyositis.

JAAD Highlights

March 2024 Issue:

1. Role of Oral Nutritional Supplements in Reducing Isotretinoin Side Effects: Analysis of how oral supplements can help mitigate the side effects of isotretinoin.

2. Infection Risks for Psoriasis Patients on JAK Inhibitors: Evaluation of infection risks associated with JAK inhibitor treatments.

3. Updates on Diagnosis and Treatment of Nail Psoriasis and Lichen Planus: Latest advancements in the treatment of these conditions.

4. Methotrexate for Pyoderma Gangrenosum: Study on the effectiveness of Methotrexate in treating pyoderma gangrenosum.

February 2024 Issue:

1. Part I: Epidemiology, Pathophysiology, and Clinical Considerations of Raynaud Phenomenon: Comprehensive review of primary and secondary Raynaud phenomenon.

2. Part II: Treatment of Raynaud Phenomenon: Current treatment options and strategies.

3. Low-Dose Oral Minoxidil for Androgenetic Alopecia: Study indicating no significant blood pressure changes with low-dose oral Minoxidil treatment for hair loss.

JEADV Highlights

March 2024 Issue:

1. Post-Inflammatory Hyperpigmentation Treatments: Systematic review of treatment effectiveness.

2. Comparative Analysis of 423 Chronic Inducible Urticaria Patients: Insights from a large patient cohort study.

3. Skin Psychosomatics in Rosacea Patients: Study on the psychosomatic aspects affecting rosacea patients.

February 2024 Issue:

1. Best Treatments for Palmoplantar Pustulosis: Evaluation of treatment outcomes.

2. Periorbital Pigment Reduction in Elderly: Analysis of effective treatments.

3. Efficacy and Safety of Home 590 nm LED vs. Clinical 1064 nm Q-Switched NdLaser for Melasma: Comparative study on melasma treatments.

4. Iris Patterns as Risk Factors for Skin Cancer in Immunosuppressed Kidney Transplant Recipients: Investigating iris patterns as potential risk indicators.

5. IL 17 and IL 23 Inhibitors' Association with Malignancies: Study examining the link between these inhibitors and cancer risks.

psoriasis treatment

BJD Highlights

April 2024 Issue:

1. 5% Topical Permethrin vs. 25% Benzyl Benzoate for Scabies Treatment: Comparative study on the effectiveness of these treatments.

2. Role of FPR1 in NOD-Like Receptor C4 Dependent Keratinocyte Activation in Skin Inflammation: Research on the molecular mechanisms involved in skin inflammation.

3. Maternal SARS-CoV-2 Infection During Pregnancy and Offspring Atopic Dermatitis Risk: Study on the impact of maternal COVID-19 infection on the risk of atopic dermatitis in offspring.

March 2024 Issue:

1. New ABCA12 Mutations Leading to Variable Erythrokeratodermia: Genetic study on the effects of new ABCA12 mutations.

2. Impact of Cumulative Exposure to Metabolic Syndrome on Psoriasis Risk: Study showing age-group specific effects of metabolic syndrome on psoriasis risk.



The research published in 2024 has provided significant advancements in understanding and treating various dermatological conditions. From new therapies and treatment guidelines to insights into disease mechanisms and patient quality of life, these studies offer valuable knowledge for both clinicians and patients in the field of dermatology.

Get the latest price? We'll respond as soon as possible(within 12 hours)

Privacy policy